Compare PubMatic Inc (PUBM) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? PubMatic Inc trades at $17.61 (market cap $860.90M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5.7× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PUBM | TVTX | |
|---|---|---|
Market Cap | $860.90M | $4.88B |
Volume | 528,167 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $19.18 | $67.52 |
52-Week Low | $6.28 | $26.79 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | $764.03M | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUBM trades at $17.64, down 4.75% today but maintains strong technical momentum with bullish moving average signals. The company reported three consecutive quarterly EPS beats despite negative annual net income margins. Recent Q2 2026 results showed 10.5% revenue growth and a significant EPS beat of $0.12 versus $0.03 expected, driven by mobile app and CTV segment strength.
Wall Street maintains bullish sentiment with 11 buy ratings and a $19.89 consensus target, representing 13% upside. Key risks include CFO transition uncertainty and competitive ad-tech landscape pressure. The stock's premium valuation (P/E 132) requires continued execution on AI-driven growth initiatives to justify current levels.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
